| 155 | 0 | 184 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 比较高孕酮状态下促排卵(PPOS)方案应用于卵巢低反应(POR)人群时，给予20 mg/d地屈孕酮口服与30 mg/d地屈孕酮口服的临床结局。方法 回顾性分析2017年1月至2022年12月在本中心进行体外受精/卵胞浆内单精子注射-胚胎移植(IVF/ICSI-ET)助孕治疗的114例患者的临床资料(共114个周期)。并根据使用的地屈孕酮剂量不同，分为地屈孕酮20 mg组(20个周期)和30 mg组(94个周期)。比较两组患者的一般资料、促排卵情况、胚胎移植情况及临床结局。结果 两组患者的女方年龄、体质量指数(BMI)、不予年限等一般资料比较均无显著性差异(P>0.05)。两组患者的促性腺激素(Gn)用量、Gn使用天数、获卵数、MⅡ卵数、扳机日LH水平及可用胚胎数比较均无显著性差异(P>0.05)。两组患者冻融胚胎移植(FET)周期的临床妊娠率、活产率及流产率比较亦无显著性差异(P>0.05)。结论 对于POR患者，PPOS方案中给予地屈孕酮20 mg口服可获得与地屈孕酮30 mg口服相似的临床结局，且地屈孕酮20 mg口服可减少药物使用量，节约用药成本，值得临床关注。但本研究样本量较小，后续仍需进一步扩大样本量、完善研究设计后进行深入探讨。
Abstract：Objective:To compare the clinical outcomes of 20 mg and 30 mg of dydrogesterone in the progestin-primed ovarian stimulation(PPOS) protocol for patients with poor ovarian response(POR).Methods:A retrospective study on clinical outcomes of 114 treatment cycles was conducted in 114 patients who underwent IVF/ICSI-ET in Reproductive Medical Center, Strategic Support Force Medical Center between January 2017 and December 2022. According to the dose of dydrogesterone, they were divided into 20 mg of dydrogesterone group with 20 cycles and 30 mg of dydrogesterone group with 94 cycles. The basic characteristics, ovulation induction, embryo transfer, and clinical outcomes were evaluated.Results:There were no significant differences in basic characteristics, body mass index, duration of infertility between the two groups(P>0.05). Moreover, there were no significant differences in the dose of gonadotropin(Gn),the duration of Gn use, the number of oocyte retrieved, the number of MⅡ oocyte, LH level on the trigger day, the number of available embryos between the two groups(P>0.05). There was no significant difference in the clinical pregnancy rate, live birth rate, and miscarriage rate between the two groups of frozen thawed embryo transfer(FET) cycles(P>0.05).Conclusions:For POR patients, similar clinical outcomes were obtained with 20 mg of dydrogesterone and 30 mg of dydrogesterone in the PPOS protocol. Dydrogesterone 20 mg orally can significantly reduce the drug dosage and save the cost of drug, which is worthy of clinical attention. However, the sample size of this study is relatively small, and further exploration is needed after expanding the sample size and improving the research design.
[1] Liu Y,Shen J,Zhang Y,et al.Controlled ovarian hyperstimulation parameters are not associated with de novo chromosomal abnormality rates and clinical pregnancy outcomes in preimplantation genetic testing[J].Front Endocrinol(Lausanne),2023,13:1080843.
[2] Kuang Y,Chen Q,Fu Y,et al.Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization[J].Fertil Steril,2015,104:62-70.
[3] Zhang J,Du M,Li Z,et al.Comparison of dydrogesterone and medroxyprogesterone in the progestin-primed ovarian stimulation protocol for patients with poor ovarian response[J].Front Endocrinol(Lausanne),2021,12:708704.
[4] Du M,Zhang J,Li Z,et al.Comparison of the cumulative live birth rates of progestin-primed ovarian stimulation and flexible GnRH antagonist protocols in patients with low prognosis[J].Front Endocrinol Lausanne,2021,12:705264.
[5] Ata B,Kalafat E.Progestin-primed ovarian stimulation:for whom,when and how?[J/OL].Reprod Biomed Online,2023,48:103639.
[6] Deng R,Wang J,He J,et al.GnRH antagonist protocol versus progestin-primed ovarian stimulation in patients with polycystic ovary syndrome:a systematic review and meta-analysis[J].Arch Gynecol Obstet,2024,309,1151-1163.
[7] Pai AH,Sung YJ,Li CJ,et al.Progestin Primed Ovarian Stimulation(PPOS) protocol yields lower euploidy rate in older patients undergoing IVF[J].Reprod Biol Endocrinol,2023,21:72.
[8] Wu S,Li Y,Wu G,et al.Nomogram to predict FSH starting dose in poor ovarian response women in progestin primed ovarian stimulation protocol[J].BMC Womens Health,2023,23:202.
[9] Wade JJ,MacLachlan V,Kovacs G.The success rate of IVF has significantly improved over the last decade[J].Aust N Z J Obstet Gynaecol,2015,55:473-476.
[10] Zhang Y,Zhang C,Shu J,et al.Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF:A systematic review and network meta-analysis[J].Hum Reprod Update,2020,26:247-263.
[11] 胡琳莉，王秀霞，张松英，等.辅助生殖技术临床关键指标质控专家共识[J].生殖医学杂志，2018,27:828-835.
[12] Cedars MI.Managing poor ovarian response in the patient with diminished ovarian reserve[J].Fertil Steril,2022,117:655-656.
[13] Szymusik I,Marianowski P,Zygula A,et al.Poor responders in IVF is there any evidence-based treatment for them?[J].Neuro Endocrinol Lett,2015,36:209.
[14] Garcia JE,Jones GS,Acosta AA,et al.Human menopausal gonadotropin/human chorionic gonadotropin follicular maturation for oocyte aspiration:Phase II,1981[J].Fertil Steril,1983,39:174-179.
[15] Ferraretti AP,La Marca A,Fauser BC,et al.ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization:the Bologna criteria[J].Hum Reprod,2011,26:1616-1624.
[16] Khurana RK,Rao V,Nayak C,et al.Comparing progesterone primed ovarian stimulation(PPOS) to GnRH antagonist protocol in oocyte donation cycles[J].J Hum Reprod Sci,2022,15:278-283.
[17] Giannelou P,Simopoulou M,Grigoriadis S,et al.The conundrum of poor ovarian response:from diagnosis to treatment[J].Diagnostics(Basel),2020,10:687.
[18] Sperduti S,Paradiso E,Anzivino C,et al.LH increases the response to FSH in granulosa-lutein cells from sub/poor-responder patients in vitro[J].Hum Reprod,2023,38:103-112.
[19] 黄云，廖花，岳林林.地屈孕酮在高孕激素状态下促排卵方案中的临床应用[J].中国当代医药，2017,24:72.
[20] 杜明泽，张俊韦，于晓娜，等.卵巢低反应人群应用高孕酮状态下促排卵方案中地屈孕酮和醋酸甲羟孕酮的对比：一项倾向性评分匹配队列研究[J].中华生殖与避孕杂志，2023,43:670-675.
[21] Nestor CC,Merkley CM,Lehman MN,et al.KNDy neurons as.the GnRH pulse generator:Recent studies in ruminants[J].Peptides,2023,164:171005.
[22] Constantin S.Targeting KNDy neurons to control GnRH pulses[J].Curr Opin Pharmacol,2022,67:102316.
[23] Siddiqui S,Mateen S,Ahmad R,et al.A brief insight into the etiology,genetics,and immunology of polycystic ovarian syndrome(PCOS)[J].J Assist Reprod Genet,2022,39:2439-2473.
[24] Wakabayashi Y,Nakada T,Murata K,et al.Neurokinin B and dynorphin A in kisspeptin neurons of the arcuate nucleus participate in generation of periodic oscillation of neural activity driving pulsatile gonadotropin-releasing hormone secretion in the goat[J].J Neurosci,2010,30:3124-3132.
[25] He W,Li X,Adekunbi D,et al.Hypothalamic effects of progesterone on regulation of the pulsatile and surge release of luteinising hormone in female rats[J].Sci Rep,2017,7:8096.
[26] Guo H,Li J,Shen X,et al.Efficacy of different progestins in women with advanced endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization-A single-center non-inferiority randomized controlled trial[J].Front Endocrinol(Lausanne),2020,11:129.
[27] Martínez F,Rodriguez-Purata J,Clua E,et al.Ovarian response in oocyte donation cycles under LH suppression with GnRH antagonist or desogestrel progestin:retrospective and comparative study[J].Gynecol Endocrinol,2019,35:884-889.
[28] Yu S,Long H,Chang HY,et al.New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF:a randomized controlled trial including 516 first IVF/ICSI cycles[J].Hum Reprod,2018,33:229-237.
[29] Schindler AE,Campagnoli C,Druckmann R,et a1.Classification and pharmacology of progestins[J].Maturitas,2008,61:171-180.
基本信息:
DOI：
中图分类号:R714.8
引用信息:
[1]倪冬冬,黄影,尚进等.卵巢低反应人群应用不同剂量地屈孕酮行高孕酮状态下促排卵方案的临床结局比较[J].生殖医学杂志,2024,33(08):997-1001.
基金信息:
博士毕业生科研启动基金(21ZX14)